APTO Aptose Biosciences Dashboard

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-classmutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Company profile

Ticker

APTO

Exchange

NASDAQ

Website

aptose.com

CEO

William Rice

Incorporated

Ontario, Canada

Location

Ontario, Canada

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...

Former names

Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.), IMUTEC PHARMA INC, LORUS THERAPEUTICS INC

SEC CIK

0000882361

Corporate docs

Articles of Incorporation & Bylaws

APTO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

1 Aug 21

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Stocks That Hit 52-Week Lows On Tuesday

27 Jul 21

During Tuesday's morning session, 216 companies made new 52-week lows.

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts

27 Jul 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)

Stocks That Hit 52-Week Lows On Friday

23 Jul 21

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street

20 Jul 21

Press releases

Pro users get this 30m faster

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

20 Jul 21

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of

Aptose Presents Highlights from EHA During Corporate Update Event

11 Jun 21

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

1 Jun 21

SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target

Aptose to Hold Corporate Update Friday, June 11th

27 May 21

Aptose to Present at Upcoming Investor Conferences

12 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

4 May 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart APTO financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	87.08M	87.08M	87.08M	87.08M	87.08M	87.08M
Cash burn (monthly)	10.1M	(positive/no burn)	5.42M	5.02M	3.46M	3.01M
Cash used (since last report)	41.28M	n/a	22.13M	20.49M	14.13M	12.31M
Cash remaining	45.8M	n/a	64.95M	66.59M	72.95M	74.77M
Runway (months of cash)	4.5	n/a	12.0	13.3	21.1	24.8

Beta Read what these cash burn values mean

Recent insider trades

APTO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jul 21	Rice William G.	Common shares	Buy	Aquire P	No	No	3.2886	6,081	20K	303,604
22 Jun 21	Whitehead Warren	Common Shares	Sell	Dispose S	No	No	3.24	9,600	31.1K	15,000
21 Jun 21	Whitehead Warren	Common Shares	Sell	Dispose S	No	No	3.35	15,400	51.59K	24,600
4 Jan 21	Ashe Carol Gail	Director Stock Option Common Shares	Grant	Aquire A	No	No	4.37	50,000	218.5K	50,000
4 Jan 21	Rafael Bejar	Employee Stock Option Common Shares	Grant	Aquire A	No	No	4.37	343,000	1.5M	343,000
4 Jan 21	Burger Denis R	Director Stock Option Common Shares	Grant	Aquire A	No	No	4.37	50,000	218.5K	50,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

APTO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Viracta Therapeutics

Management Discussion

Net loss of $55.2 million for the year ended December 31, 2020 increased by approximately $28.9 million as compared with $26.3 million for the year ended December 31, 2019, primarily as a result of an increase of $19.1 million in stock-based compensation in the current period, a combined increase in program costs and related labor costs of approximately $9.8 million on our luxeptinib development program and higher cash-based general and administrative expenses of approximately $549 thousand. These expenses were partially offset by lower costs of $545 thousand on our APTO-253 development programs.
R&D expenses increased by $12.5 million to $29.3 million for the year ended December 31, 2020 as compared with $16.8 million for the comparative period in 2019. Changes to the components of our R&D expenses presented in the table above are primarily as a result of the following activities:
General and administrative expenses for the year ended December 31, 2020 were approximately $26.5 million as compared with $10.0 million for the comparative period in 2019, an increase of approximately $16.5 million. The increase was primarily as a result of the following:

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absorption, acquired, acquisition, adequate, advice, afford, AKT, American, Amsterdam, antitumor, appointed, appointment, ASH, attract, attributed, autophagy, banking, bind, binding, Biology, biopharma, Box, broad, broadening, broader, broadly, cardiovascular, classification, clean, CMC, coagulation, Conference, confirmed, conserved, consulting, core, correlation, Cover, customarily, cutoff, de, defending, deficiency, deletion, depleting, Director, diverse, DNA, dovitinib, driven, dual, ELN, elucidating, enforce, enhanced, equally, Estoril, European, exerting, exon, expand, expanding, expired, exploit, federal, fivedosing, freshly, furnished, George, gilteritinib, GLP, governmental, group, heavily, highlighted, highlighting, hinder, Hodgkin, host, hosted, ibrutinib, implanted, Importantly, imposed, improper, Institute, Interactive, intermediate, invited, isolated, ITD, Jin, joined, Jotin, journal, Jr, Killion, Knight, luxeptinib, macroscopic, manifesting, Mantle, Marango, MCL, MDACC, mechanism, Melko, mice, microenvironment, micromolar, midostaurin, misconduct, mode, modest, modification, modified, molecular, motif, mouse, mutant, mutation, neurological, NFkB, novo, OHSU, ophthalmic, order, Page, parallel, passive, patent, pathology, PDX, permanent, PhD, poor, Portugal, presence, President, pretreated, primary, privacy, protein, published, pursue, Raji, ranging, rapid, rare, receptor, reduction, repertoire, replacement, repressor, reputational, resigned, respiratory, retain, retreated, Retreating, Rice, Robert, robust, sensitive, sensitivity, sequence, showed, Society, sorafenib, Src, stabilization, stabilize, stable, staffing, standard, stratification, subtype, sunitinib, suppressed, surprising, Synergistic, titled, TK, toxicokinetic, toxicology, transformed, Translational, treasury, typically, uncured, unique, unvested, upregulating, Vice, vitro, vivo, volume, William, World, xenograft, Yuying

Removed: AbbVie, abort, acceptance, accessibility, accomplish, accomplishment, accrual, Additionally, advance, affecting, agreed, ahead, alternative, amend, America, annually, anticipated, applied, approved, Arog, ARQ, Arqule, Aspire, assure, AstraZeneca, begin, Beigene, bring, CALQUENCE, cancelled, candidate, Cantor, carry, caution, cease, cGMP, challenging, China, choosing, commenced, commencement, commercial, commercializing, commercially, commitment, community, competitive, compliance, complying, considerably, consideration, consistent, contracted, convenience, corrective, country, coverage, criteria, cumulative, Daiichi, debt, decide, decision, decline, delayed, demand, depend, dependence, design, desired, difficulty, dilution, disease, disruption, dissatisfaction, dramatically, dropping, ease, easier, Eli, eligibility, emanating, employing, enable, enrolment, entry, exclusion, exclusive, executed, extent, failing, failure, fear, filling, Fitzgerald, foregoing, forward, generic, geopolitical, Germany, Good, granting, guarantee, harmed, healthcare, hold, Howell, IDHIFA, IMBRUVICA, immaterial, impair, importation, imposition, India, indirect, industry, infringement, initially, initiating, initiation, intensive, interrupt, Jazz, jurisdiction, Kingdom, labeled, labeling, labor, labour, license, lifted, light, Likewise, Lilly, limit, longer, manner, Medicine, member, mitigate, mitigating, move, MYLOTARG, natural, necessitate, North, obsolete, obtained, occur, operate, outbreak, packaged, packaging, packing, pandemic, partial, partially, participating, partnering, past, path, perform, performing, permission, perspective, Pfizer, pharmacology, political, precluding, predicted, prequalify, prescribe, presently, prevalence, prevention, problem, processing, Professor, profit, progressively, project, promissory, prone, prospective, qualified, reach, recommencement, recover, recruit, referral, refusal, reimbursement, rejecting, relevant, relinquish, rely, remotely, repeat, restructured, resubmit, resulted, Roche, RYDAPT, Sankyo, satisfy, schedule, scheduling, secure, seek, set, shipping, shorten, shutdown, size, sooner, specific, spite, Stephen, storing, strength, stronger, submission, supplement, suspending, suspension, sustain, sustained, taxation, terminate, terminated, terminating, termination, territory, terrorism, threat, TIBSOVO, timetable, trade, transportation, turn, UCSD, unacceptable, uncertainty, undergo, unforeseen, unreasonable, unsuccessful, VENCLEXTA, viable, war, withdrawal, withdrawing, XOSAPTA, Zanubrutinib

From filing 10-Q 2021 Q1